This paper explores current advancements in Alzheimer's disease (AD) care, treatment, and accessibility, and what improvements can be made on existing establishments of care and remedy. We examine present-day advances in optogenetics, retinal imaging, and biomarker research, as well as the implications of emerging drugs like Donanemab. Furthermore, it addresses the progressive and costly burden of Alzheimer’s care, whilst also examining the underlying social and systemic challenges. Through a thorough discussion of these developments and advancements, our paper proposes strategies for improving access to care, amplifying early detection and intervention, and supporting policy reforms to alleviate the stress on patients and their families, as well as caregivers and healthcare systems.
